Hepatocellular carcinoma

Augusto Villanueva, Yujin Hoshida, Derek Y. Chiang, Josep M. Llovet

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Hepatocellular carcinoma (HCC) is the leading cause of death among cirrhotic patients and ranks third in cancer-related mortality worldwide (1). HCC usually develops as a consequence of chronic exposure to various environmental risk factors, including chronic hepatitis B and C viral infection, alcohol consumption, aflatoxin B1 intake from contaminated food, and other agents causing liver cirrhosis (2). Hepatitis B virus (HBV) vaccination has successfully decreased the incidence of HCC cases in Asia (3), but the increase in hepatitis C virus (HCV)-related liver disease has led to an increment of HCC in Western countries (4). Treatment considerations are often complicated by the co-existence of liver cirrhosis. Thus, an accurate assessment of tumor progression and liver dysfunction determines patient prognosis and drives treatment strategy, according to the widely accepted Barcelona-Clínic Liver Cancer (BCLC; 5,6) staging system. This therapeutic algorithm is endorsed by the American and European Association for the study of the liver in their clinical management guidelines (7,8). Curative treatments have low applicability in the West because many patients are diagnosed at an advanced stage. Different studies show that less than 40% of HCC patients will be eligible for such therapies (e.g. resection, transplantation, or percutaneous ablation; 9). However, during the last 30 years, there have been major advancements in HCC management, in addition to significant milestones in the characterization of its molecular determinants (10). For example, the multi-kinase inhibitor sorafenib, represents the first systemic agent able to significantly improve overall survival in HCC patients with advanced tumors (11). This breakthrough has important implications for HCC research and the prospective design of clinical trials (6). New insights into the molecular pathogenesis will accelerate the deployment of individualized therapies for HCC.

Original languageEnglish (US)
Title of host publicationMolecular Oncology
Subtitle of host publicationCauses of Cancer and Targets for Treatment
PublisherCambridge University Press
Pages569-578
Number of pages10
ISBN (Electronic)9781139046947
ISBN (Print)9780521876629
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Villanueva, A., Hoshida, Y., Chiang, D. Y., & Llovet, J. M. (2015). Hepatocellular carcinoma. In Molecular Oncology: Causes of Cancer and Targets for Treatment (pp. 569-578). Cambridge University Press. https://doi.org/10.1017/CBO9781139046947.050